ArticleJournal of neurovirology2025
Molecular epidemiology of JC polyomavirus genotypes in PLWH from Turkey.
Article in Journal of neurovirology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundJC polyomavirus (JCPyV) is a globally prevalent human polyomavirus that establishes lifelong latency, primarily in renal tissue. Despite its global importance, molecular epidemiological data on JCPyV still remain limited.
objectivesThis study aimed to investigate the prevalence, genotype distribution, and genetic variations of JCPyV in urine and plasma samples from people living with HIV (PLWH) in Turkey. Additionally, we explored the correlation between JCPyV presence, immunological parameters, and demographic factors, providing the first molecular epidemiological report of JCPyV in this population. A prospective, multicentre, cross-sectional study was conducted on 107 PLWH and 77 healthy controls. JCPyV DNA was detected and quantified using qPCR, and VP1 gene sequencing was performed to determine viral genotypes. Phylogenetic analysis was conducted using Clustal Omega and the Neighbour-Joining method with a bootstrap value of 1000.
resultsJCPyV viruria was detected in 46% of PLWH and 18.18% of healthy individuals, with no significant association between viruria frequency and immunodeficiency severity (p > 0.05). Genotype IV was the most prevalent (37.5%), followed by Genotype I (31.25%) and Genotype II (31.25%), aligning with European epidemiological data. No Genotype III was detected. No VP1 mutations associated with PML or immune evasion were identified. However, amino acid substitutions were observed at positions 74, 92, 116, 127, and 133, warranting further investigation.
conclusionThis study provides the first molecular epidemiological analysis of JCPyV in PLWH from Turkey, demonstrating a genotype distribution consistent with European data. While no significant PML-associated VP1 mutations were detected, the identification of substitutions underscores the need for continued molecular surveillance. Understanding JCPyV genotype dynamics and immune evasion strategies is crucial for developing targeted therapeutics, including VP1-based vaccines and monoclonal antibody treatments for high-risk populations.
Indexed as
Identifiers
40353955What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.